

OnabotulinumtoxinA (Botox®)

Selected References:

- Bodkin CL, et al. 2005. OnabotulinumtoxinA therapy during pregnancy. *Mov Disord* 20(8): 1081-1082.
- Briggs J, et al. 2005. *Drugs in pregnancy and lactation*, 7th Ed. 174-175. Lippincott Williams & Wilkins: Philadelphia.
- Brin MF, et al. 2016. Pregnancy outcomes following exposure to onabotulinumtoxinA. *Pharmacoepidemiology and Drug Safety*. 25: 179-187.
- Brin, MF, et al 2023. Pregnancy outcomes in patients exposed to onabotulinumtoxinA treatment. *Neurology*. 101: e103-e113.
- Cardon BR, Smith ME, Cerrati EW. 2021 May-June. Case Series of Botulinum Toxin Administered to Pregnant Patients and Review of the Literature. *Facial Plast Surg Aesthet Med*. 23(3):187-190. De Oliveira Monteiro E. 2006. Botulinum toxin and pregnancy. *Skinmed* 5(6): 308.
- Li Yim and Weir CR. 2010. Botulinum toxin and pregnancy – cautionary tale. *Strabismus* 18(2): 65-66.
- Morgan JC, et al. 2006. Botulinum toxin A during pregnancy: a survey of treating physicians. *J Neurol Neurosurg Psychiatry* 77 (1) 117-119.
- Newman W.J., et al 2004. OnabotulinumtoxinA therapy during pregnancy. *Mov Disord* 19(11): 1384-1385.
- Polo JM, et al. 1996. Botulism and pregnancy. *Lancet* 348: 195.
- Robinson AY, Grogan PM. OnabotulinumtoxinA successfully used as migraine prophylaxis during pregnancy: a case report. *Mil Med*. 2014 Jun;179(6):e703-4.
- St. Clair EH, et al. 1975. Observations of an infant born to a mother with botulism. *J Pediatr* 87: 658.
- Wataganara T, et al. 2009. Treatment of severe achalasia during pregnancy with esophagoscopy injection of botulinum toxin A: a case report. *J Perinatol* 29(9): 639.
- Wong HT, et al. 2020. OnabotulinumtoxinA for chronic migraine during pregnancy: a real-world experience on 45 patients. *J Headache Pain*. 21(1):129.
- Wong HT, et al. 2025. OnabotulinumtoxinA treatment for chronic migraine in pregnancy: An updated report of real-world headache and pregnancy outcomes over 14 years in Hull. *Cephalalgia* 45(5):3331024251327387.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de enero de 2026.

OnabotulinumtoxinA (Botox®)

Selected References:

- Alembic Pharmaceuticals Inc. 2017. Metoprolol tartrate product labeling. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24837d82-0f3f-4482-9af0-31e5f675c30f>. Accessed 27 Jan 2026.
- Bateman BT, et al. 2016. Late pregnancy β blocker exposure and risks of neonatal hypoglycemia and bradycardia. *Pediatrics*; 138(3). pii:e20160731.
- Battarbee AN, et al. 2020. Chronic hypertension in pregnancy. *Am J Obstet Gynecol*; 222(6):532-541.
- Davis RL, et al. 2011. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. *Pharmacoepidemiol Drug Saf*. 20(2):138-145.
- Duan L, et al. 2017. β -Blocker exposure in pregnancy and risk of fetal cardiac anomalies. *JAMA Intern Med*. 177(6): 885-887.
- Duan L, et al. 2018. Beta-blocker subtypes and risk of low birth weight in newborns. *J Clin Hypertens* 20(11):1603-1609.
- Firoz T, et al. 2014. Community Level Interventions for Pre-Eclampsia (CLIP) Working Group. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. *BJOG*. 121(10):1210-1218.
- Kulas J et al. 1984. Atenolol and metoprolol. A comparison of their excretion into human breast milk. *Acta Obstet Gynecol Scand Suppl*. 118: 65-69.
- Lindeberg S et al. 1984. Disposition of the adrenergic blocker metoprolol in the late-pregnant woman, the amniotic fluid, the cord blood and the neonate. *Acta Obstet Gynecol Scand Suppl*. 118: 61-64.
- Ruys TP, et al. 2014. Cardiac medication during pregnancy, data from the ROPAC. *Int J Cardiol*. 15. 177(1):124-8.
- Sandstrom B, Regardh CG. 1980. Metoprolol excretion in breast milk. *Br J Clin Pharmacol*. 9: 518-519.
- Tamirisa KP, et al. 2022. Arrhythmias in Pregnancy. *JACC Clin Electrophysiol*. 8(1):120-135.
- Tanaka K, 2016. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. *Circ J*. 80(10):2221-2226.
- Welzel T, et al. 2021. Intrauterine Growth Retardation in Pregnant Women with Long QT Syndrome Treated with Beta-Receptor Blockers. *Neonatology*. 118(4):406-415.
- Wichman K et al. 1984. A placebo controlled trial of metoprolol in the treatment of hypertension in pregnancy. *Scand J Clin Lab Invest Suppl*. 169: 90-95.
- Xie RH, et al. 2014. Beta-blockers increase the risk of being born small for gestational age or of being institutionalised during infancy. *BJOG*. 121(9):1090-1096.
- Yakoob MY, et al. 2013. The risk of congenital malformations associated with exposure to β -blockers in pregnancy: a meta-analysis. *Hypertension* 62(2):375-381.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de enero de 2026.

OnabotulinumtoxinA (Botox®)

Selected References:

- AlHarthi A, et al. 2023. Investigating behavioral and neuronal changes in adolescent mice following prenatal exposure to electronic cigarette (e-cigarette) vapor containing nicotine. *Brain Sci*, 13(10): 1417.
- Archie S, et al. 2023. Maternal e-cigarette use can disrupt postnatal blood-brain barrier (BBB) integrity and deteriorates motor, learning and memory function: influence of sex and age. *Fluids Barriers CNS*, 20.
- Baez-Loya S, et al. 2014. Perceptions about e-cigarette safety may lead to e-smoking during pregnancy. *Bull Menninger Clin*. 78(3):243-52.
- Bednarczuk N, et al. 2022. Nicotine replacement therapy and e-cigarettes in pregnancy and infant respiratory outcomes. *Early Hum Dev*, 164:105509.
- Bell L, et al. 2023. Use of e-cigarettes in pregnancy: a systematic review of evidence published from 2020-2022. *Journal of Public Health*, 33: 315-328
- Bolumen-Lopez A, et al. 2025. Neonatal nicotine withdrawal in a newborn exposed to maternal e-cigarette use. *J Neonatal Perinatal Med*. Published online October 9, 2025.
- Cardenas VM, et al. 2019. Use of Electronic Nicotine Delivery Systems (ENDS) by pregnant women I: Risk of small-for-gestational-age birth. *Tobacco induced diseases*, 17:44.
- Centers for Disease Control and Prevention (CDC). 2018. Electronic Cigarettes. https://www.cdc.gov/tobacco/e-cigarettes/?CDC_Aref_Val=https://www.cdc.gov/tobacco/basic_information/e-cigarettes/index.htm [Accessed 4/2025].
- Centers for Disease Control and Prevention (CDC). 2023: General Information About Secondhand Smoke. https://www.cdc.gov/tobacco/secondhand-smoke/?CDC_Aref_Val=https://www.cdc.gov/tobacco/secondhand-smoke/about.html [Accessed 4/2025].
- Çetin T & Durmaz Ö. 2024. An assessment of the impact of smoking and vaping during pregnancy on placental dysfunction using shear-wave elastography. *Arch Basic Clin Res*, 6(3): 188-194.
- Chen T, et al. 2023. Ovarian toxicity of e-cigarette liquids: effects of components and high and low nicotine concentration e-cigarette liquid in vitro. *Tobacco Induced Diseases*, 21:128.
- Deprato A, et al. 2025. Associations between vaping during pregnancy and perinatal outcomes: A systematic review and meta-analysis. *J Hazard Mater.*;486:137028.
- Froggatt S, et al. 2020. The effects of prenatal cigarette and e-cigarette exposure on infant neurobehavior: A comparison to a control group. *EClinicalMedicine*, 28:10062.
- Hahn J, et al. 2014. Electronic cigarettes: overview of chemical composition and exposure estimation. *Tob Induc Dis*, 12(1):23.
- Galanti F, et al. 2023. Impact of different typologies of smoking on ovarian reserve and oocyte quality in women performing ICSI cycles: an observational prospective study. *Eur Rev Med Pharmacol Sci*. 27(11):5190-5199.
- Holmboe SA, et al. 2020. Use of e-cigarettes associates with lower sperm counts in a cross-sectional study of

young men from the general population. *Hum Reprod*, 35(7):1693-1701.

- Kahr MK, et al. 2015. A qualitative assessment of the perceived risks of electronic cigarette and hookah use in pregnancy. *BMC Public Health*. 15(1):1273.
- Kim S, Oancea SC. 2020. Electronic cigarettes may not be a “safer alternative” of conventional cigarettes during pregnancy: Evidence from the nationally representative PRAMS data. *BMC Pregnancy Childbirth*, 20(1):557.
- Kim HK, et al. 2025. Impact of conventional cigarette and electronic cigarette use on sperm quality and IVF/ICSI outcomes. *Sci Rep.* ;15(1):23714.
- Kopa-Stojak PN & Pawliczak R. 2024. Disposable electronic cigarettes – chemical composition and health effects of their use. A systematic review. *Toxicology Mechanisms and Methods*, 35(3): 250-261.
- Le AD, et al. 2025. A Preconception Cohort Study of Nicotine Vaping and Incidence of Spontaneous Abortion. *Nicotine Tob Res*. Published online July 3, 2025.
- Lin S, et al. 2023. E-cigarette use during pregnancy and its association with adverse birth outcomes in the US. *Prev Med*, 166:107375.
- McDonnell BP, et al. 2020. Electronic cigarettes and obstetric outcomes: A prospective observational study. *BJOG*, 127(6):750-756. Nanninga EK et al. 2023. Adverse maternal and infant outcomes of women who differ in smoking status: e-cigarette and tobacco cigarette users. *Int. J. Environ. Res. Public Health*, 20(3): 2632.
- Nguyen T, et al. 2018. Maternal e-cigarette exposure results in cognitive and epigenetic alterations in offspring in a mouse model. *Chemical research in toxicology*, 31(7): 601-611.
- Noël A, et al. 2020. In utero exposures to electronic-cigarette aerosols impair the *Wnt* signaling during mouse lung development. *American journal of physiology. Lung cellular and molecular physiology*, 318(4):L705-L722.
- O’Connell, A., et al. 2025. Vaping and Smoking in Pregnancy-A Meta-Analysis of Neurobehavioural Development in Prenatally Exposed Offspring. *Acta paediatrica (Oslo, Norway : 1992)*, 114(12), 3108-3121.
- Orzabal MR, et al. 2019. Chronic exposure to e-cig aerosols during early development causes vascular dysfunction and offspring growth deficits. *Translational research: the journal of laboratory and clinical medicine*, 207:70-82.
- Popham K & Kandasamy Y. 2023. The impact of smoking and nicotine exposure during pregnancy on fetal nephrogenesis: a systematic review. *Journal of Developmental Origins of Health and Disease*, 14(5): 559-569.
- Phillips L et al. 2023. Developing a taxonomy to describe offspring outcomes in studies involving pregnant mammals’ exposure to non-tobacco nicotine: a systematic scoping review. *Plos One*, 18(2).
- Sana M et al. 2023. Maternal cigarette and electronic cigarette use before pregnancy associated with the risk of hypertension and gestational hypertension. *Obstetrics & Gynecology*, 141(5S): 83S-83S.
- Sukhato K, et al. 2025. Comparative effects of electronic cigarettes and dual use of electronic and conventional cigarettes on adverse pregnancy outcomes: a systematic review and meta-analysis. *BMC Public Health*. Published online November 28, 2025.
- Suter MA, et al. 2015. Is there evidence for potential harm of electronic cigarette use in pregnancy? *Birth Defects Res A Clin Mol Teratol*, 103(3):186-95.
- Trapphoff T, et al. 2024. Consumption of hookahs, e-cigarettes, and classic cigarettes and the impact on medically assisted reproduction treatment. *Sci Rep.*;14(1):9597.
- Vallée A, et al. 2025. Maternal vaping and pregnancy adverse outcomes: A systematic review and meta-analysis. *Women Birth* ;38(5):101951.
- Walayat A et al. 2024. Maternal e-cigarette exposure alters DNA methylome, site-specific CpG and CH methylation, and transcriptomic signatures in the neonatal brain. *Sci Rep*, 14.
- Wang X, et al. 2020. Smoking and use of electronic cigarettes (vaping) in relation to preterm birth and small-for-gestational age in a 2016 U.S. national sample. *Preventative medicine*, 134:106041.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de enero de 2026.

OnabotulinumtoxinA (Botox®)

Selected References:

- Bateman BT, et al. 2016. Late pregnancy β blocker exposure and risks of neonatal hypoglycemia and bradycardia. *Pediatrics* 138(3) pii:e20160731.
- Bauer et al. 1979. Propranolol in human plasma and breast milk. *Am J Cardiol* 43(4):860-862.
- Bratton S, et al. 2024. Does atenolol use during pregnancy cause small for gestational age neonates? A meta-analysis. *Journal of Perinatal Medicine*. 52.8: 858-862.
- Davis RL, et al. 2011. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. *Pharmacoepidemiol Drug Saf.* 20(2):138-45. Duan L, et al. 2017. b-Blocker exposure in pregnancy and risk of fetal cardiac anomalies. *JAMA Intern Med* 177(6):885-887.
- Duan L, et al. 2018. Beta-blocker subtypes and risk of low birth weight in newborns. *J Clin Hypertens* 20(11):1603-1609.
- Firoz T, et al. 2014. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. *BJOG* 121(10):1210-1218.
- Fischer AJ, et al. 2021. Antiarrhythmic drugs – safety and efficacy during pregnancy. *Herzschrittmacherther Elektrophysiol* 32(2): 145-151.
- Freppel R, et al. 2024. Beta-blockers and breastfeeding: a real-life prospective study. *Eur J Clin Pharmacol.* 80(12):1937-1943.
- Halpern DG, et al. 2019. Use of medication for cardiovascular disease during pregnancy: JACC state-of-the-art review. *Journal of the American College of Cardiology.* 73.4: 457-476.
- Hutchinson S, et al. 2013. Use of common migraine treatments in breast-feeding women: A summary of recommendations. *Headache* 53(4):614-627.
- Joglar JA, et al. 2023. 2023 HRS expert consensus statement on the management of arrhythmias during pregnancy. *Heart Rhythm.* 20.10: e175-e264. Karlberg B, et al. 1974. Excretion of propranolol in human breast milk. *Aceta Pharmacol Toxicol* 34(3):222-224.
- Lennestall R, et al. 2009. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. *Eru J Clin Pharmacol* 65(6):615-625.

- Manolis TA, et al. 2020. Cardiac arrhythmias in pregnant women: need for mother and offspring protection. *Curr Med Res Opin* 36(7):1225-1243.
- Moss HB, Procci WRR. 1982. Sexual dysfunction associated with oral antihypertensive medication: a critical survey of the literature. *Gen Hosp Psych* 4(2):121-129.
- Riant P, et al. 1986. High plasma protein binding as a parameter in the selection of betablockers for lactating women. *Biochem Pharmacol* 35(24):4579-4581.
- Rosen RC, et al. 1988. Beta-blocker effects on sexual function in normal males. *Arch Sex Behav*. 17(3):241-255. Ruys TP, et al. 2014. Cardiac medication during pregnancy, data from the ROPAC. *Int J Cardiol*. 177(1):124-128.
- Salman M, et al. 2016. Erectile dysfunction: prevalence, risk factors, and involvement of antihypertensive drugs intervention. *Trop J Pharm Res* 15(4):869-876.
- Smith MT et al. 1983. Propranolol, propranolol glucuronide, and naphthoxylactic acid in breast milk and plasma. *Ther Drug Monit*. 5(1):87-93.
- Tanaka K, et al. 2016. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. *Circ J* 80(10):2221-2226. Taylor EA, Turner P. 1981. Anti-hypertensive therapy with propranolol during pregnancy and lactation. *Postgrad Med J* 57(669):427-430.
- Thorley KJ, McAinish J. 1983. Levels of the beta-blockers atenolol and propranolol in the breast milk of women treated for hypertension in pregnancy. *Biopharm Drug Dispos*. 4(3):299-301.
- Turnstall ME. 1969. The effect of propranolol on the onset of breathing at birth. *Br J Anaesth* 41(9):792.
- Welzel T, et al. 2021. Intrauterine growth retardation in pregnant women with Long QT syndrome treated with beta-receptor blockers. *Neonatology* 118(4):406-415.
- Xie RH, et al. 2014. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. *Eur J Obstet Gynecol Reprod Biol* 175:124-128.
- Xie RH, et al. 2014. Beta-blockers increase the risk of being born small for gestational age or of being institutionalized during infancy. *BJOG*. 121(9):1090-1096.
- Yakoob MY, et al. 2013. The risk of congenital malformations associated with exposure to β -blockers in pregnancy: a meta-analysis. *Hypertension* 62(2):375-381.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de enero de 2026.

OnabotulinumtoxinA (Botox®)

Selected References:

- Abdellatif M, et al. 2019. Association between exposure to macrolides and the development of infantile hypertrophic pyloric stenosis: a systematic review and meta-analysis. *Eur J Pediatr* 178(3):301-314.
- Adair CD, Gunter M, Stovall TG et al. 1998. Chlamydia in pregnancy: A randomized trial of azithromycin and erythromycin. *Obstet Gynecol* 91:165-168.
- Andersson NW, Olsen RH, Andersen JT. 2021. Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study. *BMJ*. 372:n107.
- Bahat Dinur A, et al. 2013. Fetal safety of macrolides. *Antimicrob Agents Chemother* 57(7):3307-11.
- Berard A, et al. 2015. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. *Pharmacoepidemiol Drug Saf* 24(12):1241-1248.
- Cohen I, et al. 1990. Improved pregnancy outcome following successful treatment of chlamydial infection. *JAMA* 263:3160-3163.
- Committee on Drugs, American Academy of Pediatrics. 2001. The transfer of drugs and other chemicals into human breast milk. *Pediatrics* 108:776-89.
- Damkier P, et al. 2019. In utero exposure to antibiotics and risk of congenital malformations: A population-based study. *Am J Obstet Gynecol* 221:648.e1-15.
- Fan H, et al. 2020. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. *BMJ* 368:m331.
- Flenady V, et al. 2013. Prophylactic antibiotics for inhibiting preterm labour with intact membranes. *Cochrane Database Syst Rev* 5;12:CD000246.
- FitzSimmons J et al. 1990. Chlamydial infections in pregnancy. *J Reprod Med* 31:19-22, 1986.
- Goldstein LH, et al. 2009. The safety of macrolides during lactation. *Breastfed Med* 4:157-200
- Källén B, Danielsson BR, 2014. Fetal safety of erythromycin. An update of Swedish data. *Eur J Clin Pharmacol* 70(3):355-60.
- Keskin-Arslan E, et al. 2023. Pregnancy outcomes following maternal macrolide use: A systematic review and meta-analysis. *Reprod Toxicol*; 115:124-146.
- Lin KJ, et al. 2013. Safety of macrolides during pregnancy. *Am J Obstet Gynecol* 208(3):221.e1-8.
- Lund M, et al. 2014. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. *BMJ* 11;348:g1908.
- Marlow N, et al. 2017. The ORACLE Children Study: educational outcomes at 11 years of age following antenatal prescription of erythromycin or co-amoxiclav. *Arch Dis Child Fetal Neonatal Ed* 102(2):F131-F135.
- McCormack WM et al. 1987. Effect on birth weight of erythromycin treatment of pregnant women. *Obstet Gynecol* 69:202-207.
- McGregor JA et al. 1986. Adjunctive erythromycin treatment for idiopathic preterm labor: Results of a randomized, double-blind, placebo-controlled trial. *Am J Obstet Gynecol* 154:98-103.
- Romøren M, et al. 2012. Pregnancy outcome after gestational exposure to erythromycin – a population-based register study from Norway. *Br J Clin Pharmacol* 74(6):1053-62.
- Ryan GM Jr, et al. 1990. Chlamydia trachomatis infection in pregnancy and effect of treatment on outcome. *Am J Obstet Gynecol* 162:34-39.
- Schachter J, et al. 1986. Experience with the routine use of erythromycin for chlamydial infections in pregnancy. *N Engl J Med* 314:276-9Sorensen, HT et al. 2003. Risk of infantile hypertrophic pyloric stenosis after maternal

postnatal use of macrolides. Scand J Infect Dis 35:104-6

- Shen Q, et al. 2025. Associations between urinary antibiotic exposure and semen parameters among adult men: a biomonitoring-based cross-sectional study. Environmental Pollution 375: 126335
- WHO Working Group, Bennet PN (ed). 1988. Drugs and Human Lactation. Elsevier, Amsterdam, New York, Oxford, pp. 253-4.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de enero de 2026.